Clinical Trial Update: Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing conversion from calcineurin inhibitors to Rapamune (sirolimus) versus standard therapy in established renal allograft recipients has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Kidney Failure
• Kidney Transplantation

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Graft Rejection, Kidney Failure | Phase 3 | Status: COMPLETED